BFA
NBIX icon

BlackRock Fund Advisors’s Neurocrine Biosciences NBIX Stock Holding History

BlackRock Fund Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$82M Buy
2,118,355
+108,722
+5% +$4.92M 0.02% 1348
2016
Q3 		$102M Buy
2,009,633
+64,921
+3% +$3.23M 0.02% 1046
2016
Q2 		$88.4M Sell
1,944,712
-1,278,837
-40% -$58.9M 0.02% 1070
2016
Q1 		$127M Buy
3,223,549
+53,137
+2% +$2.11M 0.03% 758
2015
Q4 		$179M Sell
3,170,412
-172,276
-5% -$8.76M 0.04% 557
2015
Q3 		$133M Buy
3,342,688
+167,405
+5% +$8.09M 0.03% 697
2015
Q2 		$152M Sell
3,175,283
-75,059
-2% -$3.18M 0.04% 656
2015
Q1 		$129M Buy
3,250,342
+401,074
+14% +$14.3M 0.03% 778
2014
Q4 		$63.7M Buy
2,849,268
+291,889
+11% +$5.53M 0.02% 1294
2014
Q3 		$40.1M Sell
2,557,379
-19,944
-0.8% -$298K 0.01% 1499
2014
Q2 		$38.2M Sell
2,577,323
-231,213
-8% -$3.26M 0.01% 1579
2014
Q1 		$45.2M Buy
2,808,536
+394,024
+16% +$6.74M 0.01% 1483
2013
Q4 		$22.6M Sell
2,414,512
-37,089
-2% -$362K 0.01% 1926
2013
Q3 		$27.8M Buy
2,451,601
+325,163
+15% +$4.47M 0.01% 1750
2013
Q2 		$28.5M Buy
+2,126,438
New +$26.1M 0.01% 1599

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Fund Advisors's NBIX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Neurocrine Biosciences (NBIX) stake by 5.4% in Q4 2016, buying an estimated $4.92M and bringing the position to 2,118,355 shares worth $82M. The position accounts for 0.02% of the portfolio, ranked #1348.

BlackRock Fund Advisors first reported a position in NBIX in Q2 2013 and has held it in 15 quarters since. The position peaked at $179M in Q4 2015. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

  • BlackRock Fund Advisors held 2,118,355 shares of Neurocrine Biosciences worth $82M as of Q4 2016.
  • BlackRock Fund Advisors bought 108,722 Neurocrine Biosciences shares in Q4 2016, an estimated $4.92M.
  • Neurocrine Biosciences made up 0.02% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1348 holding.
  • BlackRock Fund Advisors first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Fund Advisors's Neurocrine Biosciences position peaked at $179M in Q4 2015.
  • 225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.